Technical Analysis for CHRS - Coherus BioSciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| 20 DMA Resistance | Bearish | 4.81% | |
| Calm After Storm | Range Contraction | 4.81% | |
| Gapped Down | Weakness | 4.81% | |
| 20 DMA Resistance | Bearish | 4.31% | |
| 20 DMA Resistance | Bearish | 14.74% | |
| Expansion Breakdown | Bearish Swing Setup | 14.74% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 14.74% | |
| Wide Range Bar | Range Expansion | 14.74% | |
| Earnings Movers | Other | 14.74% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Rose Above 20 DMA | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
Coherus BioSciences, Inc. Description
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Treatment Of Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Adalimumab Neutropenia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.63 |
| 52 Week Low | 1.435 |
| Average Volume | 2,249,006 |
| 200-Day Moving Average | 2.96 |
| 50-Day Moving Average | 2.24 |
| 20-Day Moving Average | 2.10 |
| 10-Day Moving Average | 2.15 |
| Average True Range | 0.17 |
| RSI (14) | 50.74 |
| ADX | 14.3 |
| +DI | 15.46 |
| -DI | 23.79 |
| Chandelier Exit (Long, 3 ATRs) | 1.81 |
| Chandelier Exit (Short, 3 ATRs) | 2.32 |
| Upper Bollinger Bands | 2.31 |
| Lower Bollinger Band | 1.89 |
| Percent B (%b) | 0.69 |
| BandWidth | 19.95 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0092 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.39 | ||||
| Resistance 3 (R3) | 2.38 | 2.31 | 2.36 | ||
| Resistance 2 (R2) | 2.31 | 2.25 | 2.31 | 2.34 | |
| Resistance 1 (R1) | 2.24 | 2.22 | 2.28 | 2.25 | 2.33 |
| Pivot Point | 2.17 | 2.17 | 2.18 | 2.17 | 2.17 |
| Support 1 (S1) | 2.10 | 2.11 | 2.14 | 2.11 | 2.03 |
| Support 2 (S2) | 2.03 | 2.08 | 2.03 | 2.02 | |
| Support 3 (S3) | 1.96 | 2.03 | 2.01 | ||
| Support 4 (S4) | 1.97 |
